Joint Symposium 23
Oncology & Theranostics Committee / European Neuroendocrine Tumor Society (ENETS)
Tuesday, October 15, 16:30-18:00

Session Title
Theranostic in NEN- What is New?

Chairpersons
Marianne Pavel (Erlangen, Germany / ENETS)
Jolanta Kunikowska (Warsaw, Poland)

Programme
16:30 – 16:50  Marianne Pavel (Erlangen, Germany / ENETS): Overview on NEN Treatment - Current Options and Clinical Needs
16:50 – 17:10  Valentina Ambrosini (Bologna, Italy): Overview on NEN Diagnosis
17:10 – 17:30  Lisa Bodei (New York, United States of America): Update on PRRT - When and How
17:30 – 17:50  Damian Wild (Basel, Switzerland): New Treatment Options
17:50 – 18:00  Discussion with the Audience

Educational Objectives
1. Discussion of current treatment options available for NEN, criteria for choosing a treatment strategy and unmet clinical needs
2. Criteria for PRRT patients’ selection, diagnostic procedures to be performed, current role of PRRT in NEN patients’ therapeutic flowchart, efficacy in comparison to other current treatments, regulatory issues
3. New treatment options for NEN

Summary
The aim of this CME session, Joint with ENETS, is to focus on the diversity of currently available therapeutic options for NEN. Current clinical needs and therapeutic options (target agents, chemotherapy and PRRT) as well as diagnostic procedures to be performed before and after therapy to assess response will be discussed. Patient’s selection criteria, clinical decision flow-charts for choosing when and how to perform PRRT will be detailed. New treatment options for NEN will also be presented. Finally, considering the heterogeneous NEN presentation open discussion with the audience is planned at the end of the session.

Key Words
NEN, PET/CT, Somatostatin receptors, therapy, PRRT, novel treatment options